Athersys, Inc. Announces Publication of Phase I Data Regarding MultiStem(R) for Treating Acute Myocardial Infarction

CLEVELAND, Nov. 4, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced the online publication today in Circulation Research of results from a Phase I clinical study that found that the delivery of MultiStem® was safe and well tolerated in patients who had recently suffered an acute myocardial infarction (AMI). The data also suggest improved cardiovascular performance, particularly among patients with severely compromised heart function.